Furthermore, in late-onset AD cases, higher CSF PGRN levels were associated with more advanced disease stages and cognitive impairment, and once pathology had commenced correlated with CSF levels of soluble triggering receptor expressed on myeloid cells 2 (TREM2) [76]. The gene discussed is TREM2; the disease is Alzheimer disease.